Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer

Trial Profile

Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Imatinib (Primary) ; Gemcitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Jun 2015 as per ClinicalTrials. gov record.
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 24 May 2013 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top